LACK OF CHANGE OF LIPOPROTEIN (A) CONCENTRATION WITH IMPROVED GLYCEMIC CONTROL IN SUBJECTS WITH TYPE-II DIABETES

被引:86
|
作者
HAFFNER, SM
TUTTLE, KR
RAINWATER, DL
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,SAN ANTONIO,TX 78284
[2] SW FDN BIOMED RES,DEPT GENET,SAN ANTONIO,TX 78284
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1992年 / 41卷 / 02期
关键词
D O I
10.1016/0026-0495(92)90136-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, lipoprotein (a) [Lp(a)] has been identified as a major risk factor for coronary heart disease. No data are available on the effect of improved metabolic control on plasma Lp(a) concentrations in subjects with type II diabetes mellitus, a group at high risk for coronary heart disease. We examined the effects of improved metabolic control on plasma lipid and lipoproteins and Lp(a) concentrations in 12 subjects before and after 21 days of tight metabolic control. Glycosylated hemoglobin declined from 8.9% to 6.9% (P < .002). Lp(a) increased slightly from 21.4 to 25.8 mg/dL (P = .119) with improved metabolic control. There were no significant differences in total, low-density, or high-density cholesterol values, although the decline in triglyceride concentrations was statistically significant. The distribution of apolipoprotein (a) [apo (a)] isoforms in subjects with type II diabetes mellitus was not unusual and the apo (a) isoform patterns did not change with improved metabolic control. Although the number of subjects was small, there was no decline in Lp(a) concentrations with improved control and thus the effect of glycemic control on Lp(a) concentrations may be much smaller in type II than in type I diabetes. These results suggest that diabetic subjects with elevated Lp(a) concentrations should have intensive management of conventional cardiovascular risk factors such as high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), and blood pressure. © 1992.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 50 条
  • [21] EDUCATION AND GLUCOSE CONTROL IN TYPE-II DIABETES
    MULROW, CD
    SONKSEN, P
    CLINICAL RESEARCH, 1986, 34 (01): : A271 - A271
  • [22] EDUCATION AND GLUCOSE CONTROL IN TYPE-II DIABETES
    MULROW, CD
    SONKSEN, P
    BAILEY, S
    CLINICAL RESEARCH, 1986, 34 (02): : A829 - A829
  • [23] SUBGINGIVAL MICROFLORA ASSOCIATED WITH PERIODONTITIS IN SUBJECTS WITH TYPE-II DIABETES
    ZAMBON, JJ
    SHLOSSMAN, M
    REYNOLDS, HS
    GENCO, RJ
    JOURNAL OF DENTAL RESEARCH, 1986, 65 : 247 - 247
  • [24] The benefits of glycemic control in type II diabetes.
    Vijan, S
    Hofer, TP
    Hayward, RA
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (07) : A362 - A362
  • [25] Depressive symptoms and glycemic control in type II diabetes
    Celikel, FC
    Saatcioglu, O
    Kutluturk, F
    Cumurcu, BE
    Kisacik, B
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2005, 59 (01) : 25 - 26
  • [26] Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients
    Caixas, A
    Perez, A
    OrdonezLlanos, J
    Bonet, R
    Rigla, M
    Castellvi, A
    Bayen, L
    DeLeiva, A
    DIABETES CARE, 1997, 20 (09) : 1459 - 1461
  • [27] Lipoprotein (a) concentration and apolipoprotein (a) phenotype in subjects with type 2 diabetes mellitus
    史虹莉
    方京冲
    杨秀芳
    沈稚舟
    朱禧星
    中华医学杂志(英文版), 1998, (11) : 54 - 58
  • [28] Lipoprotein (a) concentration and apolipoprotein (a) phenotype in subjects with type 2 diabetes mellitus
    Hongli, S
    Jingchong, F
    Xiufang, Y
    Zhizhou, S
    Xixing, Z
    CHINESE MEDICAL JOURNAL, 1998, 111 (11) : 1013 - 1017
  • [29] Plasma lipoprotein(a) levels are not influenced by glycemic control in type 1 diabetes
    Pérez, A
    Carreras, G
    Caixàs, A
    Castellví, A
    Caballero, A
    Bonet, R
    Ordóñez-Lianos, J
    de Leiva, A
    DIABETES CARE, 1998, 21 (09) : 1517 - 1520
  • [30] Lipoprotein (a) concentration and apolipoprotein (a) phenotype in subjects with type 2 diabetes mellitus
    史虹莉
    方京冲
    杨秀芳
    沈稚舟
    朱禧星
    Chinese Medical Journal, 1998, (11)